Source comparison
CJC-1295 No DAC & Ipamorelin FDA Approved Status: Comparison Breakdown
CJC-1295 no DAC (Modified GRF 1-29) Not FDA-approved as a drug product Legal under research-grade chemical regulations; can be synthesized by FDA-registered facilities under cGMP Legal to compound under valid prescription; not a copy of approved drug GHRH anal
This comparison does not assign a generated winner or score.
- CJC-1295 no DAC (Modified GRF 1-29)
- Not FDA-approved as a drug product
- Legal under research-grade chemical regulations; can be synthesized by FDA-registered facilities under cGMP
- Legal to compound under valid prescription; not a copy of approved drug
- GHRH analogue. Binds to pituitary GHRH receptors to stimulate endogenous GH release
- Preclinical only (no Phase I–III human trials submitted to FDA)
- Ipamorelin
- Selective ghrelin receptor agonist (GHSR-1a). Triggers GH secretion without cortisol or prolactin elevation
- Semaglutide (Wegovy, Ozempic)
- FDA-approved (2017 for type 2 diabetes; 2021 for weight management)
- Manufactured by Novo Nordisk under FDA-approved NDA; compounded versions legal during shortage
- Legal to compound only during FDA-confirmed shortage (active as of 2026)
- GLP-1 receptor agonist. Delays gastric emptying and reduces appetite signaling
- Phase III trials completed (STEP-1, SUSTAIN series) with >15,000 participants
- The table shows the core regulatory distinction: FDA approval applies to finished drug products that have completed clinical trials and received marketing authorization. Research peptides like CJC-1295 no DAC and Ipamorelin exist in a separate category. They can be legally synthesized, compounded, and prescribed, but without the clinical validation or manufacturing oversight that approved drugs carry.